Literature DB >> 28360971

Psoriasis and Psoriatic Arthritis.

Jennifer Clay Cather1, Melodie Young1, Martin Jan Bergman2.   

Abstract

Psoriasis is a dynamic systemic disease that can have a profound affect on a patient's self-esteem. Fortunately, numerous therapeutic advances have been made over the last 10 years. In order to help patients manage their disease, healthcare providers should be aware of the modifiable risk factors that may exacerbate psoriasis. Additionally, exploring the impact the disease has on a patient and how it may change over their lifespan will help ensure appropriate therapies are used. Patients are unique so one medication will not fit all of our patients' needs. In this paper, the authors look at available treatment options for psoriasis and psoriatic arthritis. Educating psoriasis patients, in addition to collaborating with patients and other healthcare providers, may help initiate therapies that will result in patients living their lives to the fullest.

Entities:  

Year:  2017        PMID: 28360971      PMCID: PMC5367866     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  39 in total

Review 1.  Psoriasis and its comorbidities.

Authors:  Neh Onumah; Leon H Kircik
Journal:  J Drugs Dermatol       Date:  2012-05       Impact factor: 2.114

2.  Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.

Authors:  Bruce Strober; Yang Zhao; Mary Helen Tran; Ari Gnanasakthy; Judit Nyirady; Charis Papavassilis; Lauren M Nelson; Lori D McLeod; Margaret Mordin; Alice B Gottlieb; Boni E Elewski; Mark Lebwohl
Journal:  Int J Dermatol       Date:  2015-10-30       Impact factor: 2.736

3.  Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Authors:  Kim Papp; Jennifer C Cather; Les Rosoph; Howard Sofen; Richard G Langley; Robert T Matheson; ChiaChi Hu; Robert M Day
Journal:  Lancet       Date:  2012-06-29       Impact factor: 79.321

4.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Authors:  C Paul; J Cather; M Gooderham; Y Poulin; U Mrowietz; C Ferrandiz; J Crowley; C Hu; R M Stevens; K Shah; R M Day; G Girolomoni; A B Gottlieb
Journal:  Br J Dermatol       Date:  2015-11-07       Impact factor: 9.302

Review 5.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Attributable risk estimate of severe psoriasis on major cardiovascular events.

Authors:  Nehal N Mehta; YiDing Yu; Rebecca Pinnelas; Parasuram Krishnamoorthy; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  Am J Med       Date:  2011-08       Impact factor: 4.965

Review 7.  Childhood psoriasis.

Authors:  Sandrine Benoit; Henning Hamm
Journal:  Clin Dermatol       Date:  2007 Nov-Dec       Impact factor: 3.541

8.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

9.  Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  J Rheumatol       Date:  2015-12-15       Impact factor: 4.666

10.  Pediatric psoriasis: an update.

Authors:  Nanette B Silverberg
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more
  4 in total

1.  Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Authors:  Philip Brenner; Anna Citarella; Louise Wingård; Anders Sundström
Journal:  BMC Rheumatol       Date:  2020-02-12

2.  Translation, cultural adaptation and validation of the Somatic Symptom Scale-8 (SSS-8) for the Brazilian Portuguese language.

Authors:  Camila Fernandes Pollo; Silmara Meneguin; Hélio Amante Miot; César de Oliveira
Journal:  BMC Prim Care       Date:  2022-09-05

Review 3.  Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.

Authors:  Anniina T Virtanen; Teemu Haikarainen; Juuli Raivola; Olli Silvennoinen
Journal:  BioDrugs       Date:  2019-02       Impact factor: 5.807

Review 4.  Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.

Authors:  Jason E Hawkes; Kyoungah See; Russel Burge; Stephanie Strakbein; Missy McKean-Matthews; Daniel Saure; Melinda Gooderham; Craig Leonardi
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.